Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial
Takayuki Sumiyoshi(University of British Columbia), Himisha Beltran(Dana-Farber Cancer Institute), Sheng‐Yu Ku(Roswell Park Comprehensive Cancer Center), Mary‐Ellen Taplin(University of Massachusetts Chan Medical School), Michael Sigouros(Cornell University), Ladan Fazli, Matti Annala(Tampere University), Andrea Sboner(Cornell University), Susan Halabi(Duke Medical Center), Alexander W. Wyatt(University of British Columbia), Martin Gleave(University of British Columbia), Kei Mizuno(Dana-Farber Cancer Institute), Evan W. Warner(Guardant (United States)), Xiaofei Wang(Sichuan University), Jeffrey P. Simko(University of California, San Francisco), Kevin Beja(University of British Columbia), James A. Eastham(Memorial Sloan Kettering Cancer Center), Michael J. Morris(Dana-Farber Cancer Institute)
Cited by 9
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k